PEACHI header v5 FP7-gen-RGB EU flag

Prevention of Hepatitis C Virus (HCV) and HIV-1 Co-Infections

A collaborative project financed by the EC Framework Programme 7

PEACHI-04 Clinical Trial Update

Recruitment is going well and is now 50% complete for the clinical trial PEACHI-04 (evaluation of the safety and immunogenicity of simultaneous prime-boost immunisations with candidate HCV and HIV-1 vaccines). For more information click here.

 

PEACHI-02 Clinical Trial Update

Recruitment has now commenced for the clinical trial PEACHI-02 (evaluation of the safety and immunogenicity of prime-boost immunisations with candidate HCV vaccines in HIV seropositive individuals) at both trial sites, St James's Hospital Dublin, Ireland and Kantonsspital St. Gallen, Switzerland.

 

For more news, click here.

News

Contact Us

The goal of the PEACHI project is to develop simple, affordable and effective vaccine strategies that can be given alone or in combination to prevent hepatitis C virus (HCV), human immunodeficiency virus type 1 (HIV-1) and co-infection.

 

The vaccines are based on novel and powerful viral vectors for in vivo delivery of antigens. Read more about the project here... 

 

This goal requires a multidisciplinary approach in which diverse expertise and technologies converge.

 

PEACHI is a unique consortium that consists of cutting edge clinical and scientific expertise, partnered with industry. In the last two years partnership members have employed viral vectored technology to develop the most immunogenic HIV-1 and HCV vaccines described to date.

If you have any questions regarding PEACHI please contact the team at the following email address:

peachi@ndm.ox.ac.uk